Last reviewed · How we verify

SPM 929 — Competitive Intelligence Brief

SPM 929 (SPM 929) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry.

phase 3 Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

SPM 929 (SPM 929) — UCB Pharma. SPM 929 is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SPM 929 TARGET SPM 929 UCB Pharma phase 3 Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter
Trintellix vortioxetine Takeda marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor 2013-01-01
Fetzima LEVOMILNACIPRAN AbbVie marketed Serotonin and Norepinephrine Reuptake Inhibitor Sodium-dependent serotonin transporter 2013-01-01
Pristiq desvenlafaxine Alembic Pharms Ltd marketed Serotonin and Norepinephrine Reuptake Inhibitor Sodium-dependent serotonin transporter 2008-01-01
Celexa CITALOPRAM AbbVie marketed Serotonin Reuptake Inhibitor Sodium-dependent serotonin transporter 1998-01-01
Plavix clopidogrel Generic (originally Sanofi/BMS) marketed Thienopyridine antiplatelet agent Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter 1997-11-17
Racemic Sibutramine SIBUTRAMINE marketed Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic Sodium-dependent serotonin transporter 1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

  1. University of Texas Southwestern Medical Center · 3 drugs in this class
  2. Johns Hopkins University · 2 drugs in this class
  3. GlaxoSmithKline · 2 drugs in this class
  4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  5. Guangdong Provincial People's Hospital · 1 drug in this class
  6. Janssen Research & Development, LLC · 1 drug in this class
  7. Medical University of Vienna · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. Fundació Sant Joan de Déu · 1 drug in this class
  10. Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPM 929 — Competitive Intelligence Brief. https://druglandscape.com/ci/spm-929. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: